<DOC>
	<DOCNO>NCT02010944</DOCNO>
	<brief_summary>This study compare pharmacokinetics ( PK ) , safety tolerability fix dose combination ( FDC ) tablets contain solifenacin succinate mirabegron co-administration single entity tablet ( SET ) , three dose strength .</brief_summary>
	<brief_title>A Study Compare How Much Solifenacin Succinate Mirabegron Reach Blood When Administered Together Fixed-dose Combination Tablets With Single Individual Tablets Same Medications Three Dose Levels</brief_title>
	<detailed_description>There three parallel group 24 healthy male female subject ( minimum 10 subject per gender ) . Each group receive one dose strength . The study utilize partial replicate cross-over design three period subject receive strength either FDC SET formulation twice . Screening take place within 21 day admission subject admit Day -1 . Dosing take place Day 1 , overnight fast least 10 hour . Subjects remain fasted 4 hour post-dose . There wash-out period least 14 day dose administration . Subjects discharge Day 4 return clinical unit Days 5 , 6 , 7 , 9 11 outpatient assessment . An End-of-Study Visit ( ESV ) take place Day 11 Period 3 within 7-14 day discontinuation .</detailed_description>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Male subject must agree donate semen day first dose 3 month last discharge practice effective contraceptive method female sexual partner prevent pregnancy . Female subject must nonchild bear potential , i.e . postmenopausal , surgically sterilize , hysterectomy medical history , practice highly effective nonhormonal birth control . Female subject pregnant , pregnant within 6 month screen breastfeed within 3 month screen . Known suspected hypersensitivity solifenacin succinate , mirabegron component formulation use . The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission clinical unit . Any significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Solifenacin</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Fixed-dose combination ( FDC )</keyword>
	<keyword>Single Entity Tablet ( SET )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioavailability</keyword>
</DOC>